China Digest: Atom Bioscience, Shuzhilian in funding news

China Digest: Atom Bioscience, Shuzhilian in funding news

Hangzhou, China. Photo: Alessio Lin

Jiangsu Atom Bioscience & Pharmaceutical Co. Ltd (Atom Bioscience) has raised 150 million yuan ($22 million) in a Series B round led by Livzon Pharmaceutical, a wholly-owned investment platform Zhuhai Lizhu Pharmaceutical Equity Investment Management Co., Ltd. In a separate development, China’s premium big data solution company Chengdu Shuzhilian Technology Company has also secured a similar amount from GF Venture Capital and existing investor Yinxinggu Capital.

Atom Bioscience raises $22m 

Jiangsu Atom Bioscience & Pharmaceutical Co. Ltd (Atom Bioscience) has raised 150 million yuan ($22 million) in a Series B funding round led by Livzon Pharmaceutical, a wholly-owned investment platform Zhuhai Lizhu Pharmaceutical Equity Investment Management Co., Ltd.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter